Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma.
CAR-T
CD20 targeted
Cytokine
Efficacy
NSG mice
Non-Hodgkin's lymphoma
Journal
Discover. Oncology
ISSN: 2730-6011
Titre abrégé: Discov Oncol
Pays: United States
ID NLM: 101775142
Informations de publication
Date de publication:
09 Nov 2022
09 Nov 2022
Historique:
received:
08
08
2022
accepted:
02
11
2022
entrez:
9
11
2022
pubmed:
10
11
2022
medline:
10
11
2022
Statut:
epublish
Résumé
A 4-1BB/CD3-ζ-costimulated CAR-T against CD20 (CAR-T20) was subjected to a systemic efficacy evaluation in a cell co-culture model, and NOD-SCID IL-2 receptor gamma null mice (short for NSG mice) were xenografted with human Burkitt's lymphoma Raji cells. CAR-T20 cells were incubated with target cells (K562, K562 CD20 or Raji cells) at ratios of 10:1 and 5:1 for 24 h, and the killing rate was estimated by an LDH cytotoxicity assay. To evaluate the effect of CAR-T20 on the survival time of tumor-bearing animals, 30 NSG mice were employed, and Raji-Luc cells (5 × 10 CAR-T20 cells had a specific killing effect on CD20-expressing cells in vitro. At a dose of 1 × 10 The effective dose of CAR-T20 in mice starts from 1 × 10
Sections du résumé
BACKGROUND
BACKGROUND
A 4-1BB/CD3-ζ-costimulated CAR-T against CD20 (CAR-T20) was subjected to a systemic efficacy evaluation in a cell co-culture model, and NOD-SCID IL-2 receptor gamma null mice (short for NSG mice) were xenografted with human Burkitt's lymphoma Raji cells.
METHODS
METHODS
CAR-T20 cells were incubated with target cells (K562, K562 CD20 or Raji cells) at ratios of 10:1 and 5:1 for 24 h, and the killing rate was estimated by an LDH cytotoxicity assay. To evaluate the effect of CAR-T20 on the survival time of tumor-bearing animals, 30 NSG mice were employed, and Raji-Luc cells (5 × 10
RESULTS
RESULTS
CAR-T20 cells had a specific killing effect on CD20-expressing cells in vitro. At a dose of 1 × 10
CONCLUSION
CONCLUSIONS
The effective dose of CAR-T20 in mice starts from 1 × 10
Identifiants
pubmed: 36352168
doi: 10.1007/s12672-022-00588-w
pii: 10.1007/s12672-022-00588-w
pmc: PMC9646688
doi:
Types de publication
Journal Article
Langues
eng
Pagination
122Subventions
Organisme : National Key Research and Development Program
ID : 2021YFA1101602
Organisme : Chinese Academy of Sciences Strategic Leading Science and Technology Project
ID : XDA16040502
Informations de copyright
© 2022. The Author(s).
Références
Vaccines (Basel). 2020 Nov 27;8(4):
pubmed: 33260966
Science. 2020 Aug 14;369(6505):793-799
pubmed: 32792392
Ann Transl Med. 2019 Dec;7(23):735
pubmed: 32042751
Nat Immunol. 2003 Sep;4(9):835-42
pubmed: 12942084
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Cancer Immunol Res. 2015 Apr;3(4):333-44
pubmed: 25492700
Expert Opin Biol Ther. 2021 Feb;21(2):161-181
pubmed: 32933335
Front Oncol. 2019 Mar 12;9:146
pubmed: 30915277
Am J Clin Pathol. 2016 May;145(5):591-603
pubmed: 27247365
Adv Ther. 2017 Oct;34(10):2232-2273
pubmed: 28983798
Blood Cancer J. 2021 Apr 6;11(4):69
pubmed: 33824268
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
Blood. 2015 Jan 1;125(1):22-32
pubmed: 25499448
Cytotherapy. 2022 Oct;24(10):1026-1034
pubmed: 35691818
Cancer Immunol Res. 2016 Jun;4(6):509-19
pubmed: 27197068
Ann Transl Med. 2021 Dec;9(23):1713
pubmed: 35071407
Blood. 2008 Sep 15;112(6):2261-71
pubmed: 18509084
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Front Immunol. 2017 Oct 04;8:1245
pubmed: 29046676
J Clin Invest. 2020 Apr 1;130(4):1576-1585
pubmed: 32039913
Blood. 2012 Apr 26;119(17):3940-50
pubmed: 22308288
Am J Hematol. 2021 Oct 1;96(10):1295-1312
pubmed: 34310745
Clin Transl Immunology. 2022 Feb 02;11(2):e1373
pubmed: 35136603
Blood. 2012 Mar 22;119(12):2709-20
pubmed: 22160384
Exp Hematol Oncol. 2020 Jun 08;9:11
pubmed: 32523801
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Mol Ther. 2016 Nov;24(11):1987-1999
pubmed: 27439899
J Hematol Oncol. 2017 Feb 21;10(1):53
pubmed: 28222796
Nat Rev Cancer. 2014 Aug;14(8):517-34
pubmed: 25008267
Am J Hematol. 2019 Oct;94(10):1113-1122
pubmed: 31321805
Science. 2003 Apr 11;300(5617):337-9
pubmed: 12690201
Biomark Res. 2021 Jul 13;9(1):58
pubmed: 34256851
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Cancer Immunol Res. 2015 May;3(5):483-94
pubmed: 25711536
Int J Mol Sci. 2019 Mar 14;20(6):
pubmed: 30875739
N Engl J Med. 2020 Apr 2;382(14):1331-1342
pubmed: 32242358
Oncoimmunology. 2017 Jun 20;6(9):e1341031
pubmed: 28932644